Correction to: Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase
Correction to:Clinical and Translational Gastroenterology2020;11(3):e00140. https://doi.org/10.14309/ctg.0000000000000140
In the March 2020 issue of Clinical and Translational Gastroenterology, in “Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase” the authors would like to revise the Study Highlights section. The updated Study Highlights appears below.
WHAT IS KNOWN
- ✓ Antiviral therapy is not recommended for patients with hepatitis B e antigen-positive chronic hepatitis B virus infection who have persistently elevated but normal alanine aminotransferase (pEDNA group).
- ✓ There is little consensus regarding early NUC treatment for pEDNA group.
WHAT IS NEW HERE
- ✓ The cumulative hepatocellular carcinoma risk in the pEDNA group was minimal comparable with that of the inactive carrier group.
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology
- ✓ Among untreated pEDNA group, patients with an intermediate serum HBV DNA level are more likely to develop HCC. Further studies are needed.